1. Home
  2. GNL vs ZYME Comparison

GNL vs ZYME Comparison

Compare GNL & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Global Net Lease Inc.

GNL

Global Net Lease Inc.

HOLD

Current Price

$9.53

Market Cap

2.0B

Sector

Real Estate

ML Signal

HOLD

Logo Zymeworks Inc.

ZYME

Zymeworks Inc.

HOLD

Current Price

$27.94

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GNL
ZYME
Founded
2011
2003
Country
United States
United States
Employees
56
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.9B
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
GNL
ZYME
Price
$9.53
$27.94
Analyst Decision
Buy
Strong Buy
Analyst Count
3
11
Target Price
$9.67
$38.90
AVG Volume (30 Days)
1.4M
536.9K
Earning Date
05-05-2026
05-07-2026
Dividend Yield
8.09%
N/A
EPS Growth
N/A
33.33
EPS
N/A
N/A
Revenue
N/A
$105,965,000.00
Revenue This Year
N/A
$183.10
Revenue Next Year
$1.95
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
38.87
52 Week Low
$6.77
$10.89
52 Week High
$10.04
$29.75

Technical Indicators

Market Signals
Indicator
GNL
ZYME
Relative Strength Index (RSI) 51.84 60.65
Support Level $9.17 $22.28
Resistance Level $9.75 $28.49
Average True Range (ATR) 0.17 1.11
MACD -0.01 0.03
Stochastic Oscillator 46.34 58.67

Price Performance

Historical Comparison
GNL
ZYME

About GNL Global Net Lease Inc.

Global Net Lease Inc is a real estate investment trust that manages a globally diversified portfolio of commercial real estate properties. The company is engaged in the ownership, management, operation, lease, acquisition, investment, and sale of the portfolio assets. Its segments include Industrial & Distribution, Retail, and Office. The company derives maximum revenue from the Industrial and Distribution segment. The company geographically operates in the United States, the United Kingdom, Canada, and Europe.

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Share on Social Networks: